<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00978068</url>
  </required_header>
  <id_info>
    <org_study_id>H5747-34097</org_study_id>
    <secondary_id>NIH PO1 HD059454</secondary_id>
    <secondary_id>2009-114</secondary_id>
    <secondary_id>HS-620</secondary_id>
    <secondary_id>551/ESR/NDA/DID-08/09</secondary_id>
    <secondary_id>H5741-34097 and 10-00991</secondary_id>
    <nct_id>NCT00978068</nct_id>
  </id_info>
  <brief_title>HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children</brief_title>
  <acronym>PROMOTE-PEDS</acronym>
  <official_title>A Randomized Open Label Trial of HIV Protease Inhibitors for the Prevention of Malaria in HIV-Infected Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HIV and malaria are major causes of morbidity and mortality in Sub-Saharan Africa and
      children bear the greatest brunt of both diseases. No single existing intervention is likely
      to control malaria in Africa. Rather, improvements in malaria prevention are likely to come
      from strategies that employ multiple proven interventions targeting different populations.
      HIV-infected children represent one of the most vulnerable subpopulations in these countries.
      It is possible that the use of protease inhibitor (PI) - based antiretroviral therapy (ART)
      in HIV-infected children living in areas of high malaria transmission could prevent malaria
      in this vulnerable population. An effective remedy that offers the possibility to further
      reduce malaria risk, such as PIs, is highly desirable. This study will determine whether a PI
      based ART regimen will reduce malaria among children living in a malaria endemic area of
      Uganda and receiving insecticide-treated bed nets (ITN) and TS. This study will compare two
      different ART regimens. Children enrolled in the study will start or continue to receive
      either standard Ugandan first line treatment ART regimen (NNRTI+2 NRTIs) or an ART regimen
      containing the HIV protease inhibitor (lopinavir/ritonavir +2 NRTIs) and followed for a
      period of 24 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, single site, randomized clinical trial comparing PI-based ART to
      NNRTI-based ART for the prevention of malaria in HIV-infected children. The two ART drug
      regimens that will be used include: Treatment arm 1. LPV/r + 2 NRTIs and Treatment arm 2. NVP
      or EFV + 2 NRTIs. The study is designed to test the hypothesis that children receiving a
      PI-based ART regimen will have lower the incidence of malaria compared to children receiving
      an NNRTI- based ART regimen. The primary study endpoint of the study is malaria incidence.

      The study site will be the Tororo District Hospital campus situated in Eastern Uganda, an
      area of high malaria transmission. Using convenience sampling, 300 HIV-infected children
      identified from the Tororo community aged 2 months to &lt;11 years either eligible for
      ART-initiation or already receiving a first line ART regimen with HIV RNA&lt;400 copies/ml will
      be evaluated for enrollment.

      Eligible children will be randomized at enrollment to receive either a PI- based or an
      NNRTI-based ART regimen. At enrollment, all study participants will receive a long lasting
      ITN as part of a basic care package including a safe water vessel and multivitamins and given
      TS chemoprophylaxis, as per current standard of care for HIV-infected children in Uganda. On
      the day of ART initiation, patients will be counseled about the importance of adherence to
      ART and possible ART related toxicities. After 2 weeks, patients will be seen to assess
      adherence and toxicity to study medications by interview and clinical examination. Apart from
      this visit at week 2, patients will be seen at 4 week intervals timed from ART-initiation.
      Assessment of adherence will also be done for TS prophylaxis, ITN use and ART. Assessment of
      adherence to ART will be done by self report of missed doses and pill counts.

      Participants will receive all routine and acute medical care at a designated study clinic
      open 7 days a week from 8 a.m. to 5 p.m. Parents/guardians will be asked to bring their child
      to the study clinic for all medical care. If after hours, they will be instructed to bring
      them to Tororo District Hospital premises (where the study clinic is located) and request
      that the study physician on-call be contacted. They will be followed for at least 24 months
      and up to 3 years. They will be seen monthly for routine assessments with laboratory
      evaluations done at every 3 months. At these visits, the study protocol will be reinforced
      with discussion regarding the need to come to the study clinic promptly upon the onset of any
      illness and to avoid use of outside medications. Study participants will also be followed
      closely for adverse events potentially due to study drugs and for malaria and HIV treatment
      outcomes. During the follow-up period, all patients presenting to the clinic with a new
      episode of fever will undergo standard evaluation (history, physical examination) and
      Giemsa-stained blood smear for the diagnosis of malaria.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence-density of Malaria Defined as the Number of Incident Episodes of Malaria Per Time at Risk.</measure>
    <time_frame>Time from randomization to at least 24 months of follow up or until end of the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Uncomplicated Malaria Episodes With Accompanying Adverse Events That Occurred in the 28 Days Following Antimalarial Therapy</measure>
    <time_frame>28 days after antimalarial therapy</time_frame>
    <description>The rates of adverse events, defined as severity grade 2 or higher that are possibly, probably or definitely related to study drugs over the course of the 28-day period after antimalarial therapy with artemether-lumefantrine (AL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence-density of Malaria Defined as the Number of Incident Episodes of Complicated Malaria Per Time at Risk.</measure>
    <time_frame>Time from randomization to at least 24 months of follow up or until end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimates of the 6-month Risk of a First Episode of Malaria</measure>
    <time_frame>Enrollment to 6 months follow up</time_frame>
    <description>To assess the effect of ART independently of potential interactions with antimalarial therapy after treatment for malaria, we compared the two groups with respect to the time to the first episode of malaria. Cumulative risk was estimated using the Kaplan-Meier product-limit formula.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-day Risk of Recurrent Parasitemia</measure>
    <time_frame>28 days after antimalarial therapy</time_frame>
    <description>To assess the effect of potential interactions between ART and artemether-lumefantrine, the risks of recurrent parasitemia at 28 days were compared between the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>63-day Risk of Recurrent Malaria</measure>
    <time_frame>28 days after antimalarial therapy</time_frame>
    <description>To assess the effect of potential interactions between ART and artemether-lumefantrine, the risks of recurrent malaria at 63 days were compared between the two groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">176</enrollment>
  <condition>Malaria</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Lopinavir/ritonavir (LPV/r) +2 NRTI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lopinavir/ritonavir (LPV/r) +2 nucleoside reverse transcriptase inhibitor (NRTI)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nevirapine (NVP) or Efavirenz (EFV) +2 NRTI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nevirapine (NVP) or Efavirenz (EFV) +2 nucleoside reverse transcriptase inhibitor (NRTI)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/Ritonavir (LPV/r)</intervention_name>
    <arm_group_label>Lopinavir/ritonavir (LPV/r) +2 NRTI</arm_group_label>
    <other_name>Aluvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine (NVP)</intervention_name>
    <description>NVP will be used for children &lt; 3 years of age</description>
    <arm_group_label>Nevirapine (NVP) or Efavirenz (EFV) +2 NRTI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz (EFV)</intervention_name>
    <description>EFV for children ≥3 years of age</description>
    <arm_group_label>Nevirapine (NVP) or Efavirenz (EFV) +2 NRTI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2 nucleoside reverse transcriptase inhibitor (NRTI)</intervention_name>
    <description>The same NRTI choice strategy will be used for both arms. Lamivudine will be used with all children. The second NRTI will be zidovudine unless the participant has a hemoglobin &lt; 8 gm/dL, in which case it will be Abacavir. Stavudine will be used in the event that a participant is unable to take Abacavir for safety or other reasons.</description>
    <arm_group_label>Lopinavir/ritonavir (LPV/r) +2 NRTI</arm_group_label>
    <arm_group_label>Nevirapine (NVP) or Efavirenz (EFV) +2 NRTI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Age 2 months to &lt; 11 years

          2. Confirmed HIV diagnosis. i. Children &gt; 18 months: Documentation of HIV status must
             come from two assays. Assays include DNA PCR, HIV RNA, Western blot, or rapid HIV
             antibody test ii. Children &lt; 18 months: Documentation will be DNA PCR confirmation
             only along with documentation of testing from the referral entity

          3. ART-naïve patients eligible for ART initiation per WHO/Uganda guidelines (see Table 1)
             or Patients receiving first line ART regimen with NNRTI +2 NRTI with at least one HIV
             RNA &lt;400 copies/ml within the past 6 months

          4. Agreement to come to the study clinic for any febrile episode or other illness

          5. Agreement to avoid medications administered outside study protocol

          6. Provision of informed consent by parent/guardian and agreement to have child's care at
             the clinical site

          7. Lives within 50 km of study site

        Exclusion criteria:

          1. ART-naïve children: children or their mothers that have received any dose of
             Nevirapine in the past 24 months

          2. Active medical problem requiring in-patient evaluation at the time of screening or
             enrollment

          3. History of cardiac conduction disorder or known significant cardiac structural defect

          4. Children receiving any disallowed medications (see section 4.3)

          5. Moderate, Severe or Life-threatening (Grade 2, 3, or 4) AST or ALT found within 4
             weeks prior to enrollment:

               -  AST: &gt;113U/L (&gt;2.5xULN)

               -  ALT: &gt;113U/L (&gt;2.5xULN)

          6. Life-threatening (Grade 4) screening laboratory value found within 4 weeks prior to
             enrollment for the following:

               -  Absolute neutrophil count: &lt;500 mm3

               -  Hemoglobin: &lt;6.5 g/dL

               -  Creatinine: &gt;3.5xULN

               -  Platelets: &lt;25,000/mm3
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diane V Havlir, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Moses R Kamya MBChB, MMed, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Makerere University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Grant Dorsey, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ted Ruel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jane Achan, MBChB, MPed</last_name>
    <role>Principal Investigator</role>
    <affiliation>Makerere University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IDRC - Tororo Research Clinic</name>
      <address>
        <city>Tororo</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <results_reference>
    <citation>Achan J, Kakuru A, Ikilezi G, Ruel T, Clark TD, Nsanzabana C, Charlebois E, Aweeka F, Dorsey G, Rosenthal PJ, Havlir D, Kamya MR. Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children. N Engl J Med. 2012 Nov 29;367(22):2110-8. doi: 10.1056/NEJMoa1200501.</citation>
    <PMID>23190222</PMID>
  </results_reference>
  <results_reference>
    <citation>Ikilezi G, Achan J, Kakuru A, Ruel T, Charlebois E, Clark TD, Rosenthal PJ, Havlir D, Kamya MR, Dorsey G. Prevalence of asymptomatic parasitemia and gametocytemia among HIV-infected Ugandan children randomized to receive different antiretroviral therapies. Am J Trop Med Hyg. 2013 Apr;88(4):744-6. doi: 10.4269/ajtmh.12-0658. Epub 2013 Jan 28.</citation>
    <PMID>23358639</PMID>
  </results_reference>
  <results_reference>
    <citation>Nsanzabana C, Rosenthal PJ. In vitro activity of antiretroviral drugs against Plasmodium falciparum. Antimicrob Agents Chemother. 2011 Nov;55(11):5073-7. doi: 10.1128/AAC.05130-11. Epub 2011 Aug 29.</citation>
    <PMID>21876053</PMID>
  </results_reference>
  <results_reference>
    <citation>Ruel TD, Kakuru A, Ikilezi G, Mwangwa F, Dorsey G, Rosenthal PJ, Charlebois E, Havlir D, Kamya M, Achan J. Virologic and immunologic outcomes of HIV-infected Ugandan children randomized to lopinavir/ritonavir or nonnucleoside reverse transcriptase inhibitor therapy. J Acquir Immune Defic Syndr. 2014 Apr 15;65(5):535-41. doi: 10.1097/QAI.0000000000000071.</citation>
    <PMID>24326597</PMID>
  </results_reference>
  <results_reference>
    <citation>Kakuru A, Achan J, Muhindo MK, Ikilezi G, Arinaitwe E, Mwangwa F, Ruel T, Clark TD, Charlebois E, Rosenthal PJ, Havlir D, Kamya MR, Tappero JW, Dorsey G. Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan children. Clin Infect Dis. 2014 Aug 1;59(3):446-53. doi: 10.1093/cid/ciu286. Epub 2014 Apr 23.</citation>
    <PMID>24759826</PMID>
  </results_reference>
  <results_reference>
    <citation>Bartelink IH, Savic RM, Dorsey G, Ruel T, Gingrich D, Scherpbier HJ, Capparelli E, Jullien V, Young SL, Achan J, Plenty A, Charlebois E, Kamya M, Havlir D, Aweeka F. The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, Uganda. Pediatr Infect Dis J. 2015 Mar;34(3):e63-70. doi: 10.1097/INF.0000000000000603.</citation>
    <PMID>25742090</PMID>
  </results_reference>
  <results_reference>
    <citation>Achan J, Kakuru A, Ikilezi G, Mwangwa F, Plenty A, Charlebois E, Young S, Havlir D, Kamya M, Ruel T. Growth Recovery Among HIV-infected Children Randomized to Lopinavir/Ritonavir or NNRTI-based Antiretroviral Therapy. Pediatr Infect Dis J. 2016 Dec;35(12):1329-1332.</citation>
    <PMID>27580060</PMID>
  </results_reference>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>September 14, 2009</study_first_submitted>
  <study_first_submitted_qc>September 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2009</study_first_posted>
  <results_first_submitted>November 18, 2015</results_first_submitted>
  <results_first_submitted_qc>December 5, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 28, 2018</results_first_posted>
  <last_update_submitted>December 5, 2018</last_update_submitted>
  <last_update_submitted_qc>December 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatric HIV</keyword>
  <keyword>Malaria</keyword>
  <keyword>Uganda</keyword>
  <keyword>Nevirapine</keyword>
  <keyword>Zidovudine</keyword>
  <keyword>Lamivudine</keyword>
  <keyword>Lopinavir/ritonavir</keyword>
  <keyword>Stavudine</keyword>
  <keyword>Efavirenz</keyword>
  <keyword>HIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Children were recruited from September 2009 through July 2011.</recruitment_details>
      <pre_assignment_details>A total of 404 children were screened for eligibility; 228 were found not to be eligible. The main reasons for ineligibility were:
136 Were not eligible for ART 34 Were on ART with detectable viral load 32 Were HIV- 8 Had not received ART but had prior exposure to nevirapine</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>LPV/r + 2 NRTIs</title>
          <description>LPV/r + 2 NRTIs: Group 1
Lopinavir/ritonavir (LPV/r) +2 nucleoside reverse transcriptase inhibitor (NRTI)
The same NRTI choice strategy will be used for both arms. Lamivudine will be used with all children. The second NRTI will be zidovudine unless the participant has a hemoglobin &lt; 8 gm/dL, in which case it will be Abacavir. Stavudine will be used in the event that a participant is unable to take Abacavir for safety or other reasons.</description>
        </group>
        <group group_id="P2">
          <title>NVP or EFV + 2 NRTIs</title>
          <description>NVP or EFV + 2 NRTIs: Group 2
Nevirapine (NVP) or Efavirenz (EFV) + 2 NRTI
NVP will be used for children &lt; 3 years of age and EFV for children ≥3 years of age. The same NRTI choice strategy will be used for both arms. Lamivudine will be used with all children. The second NRTI will be zidovudine unless the participant has a hemoglobin &lt; 8 gm/dL, in which case it will be stavudine.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="89"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Initiated Study Drugs</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="86"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Were Awaiting Initiation of ART</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to Comply with Study</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LPV/r + 2 NRTIs</title>
          <description>LPV/r + 2 NRTIs: Group 1
Lopinavir/ritonavir (LPV/r) +2 nucleoside reverse transcriptase inhibitor (NRTI)
The same NRTI choice strategy will be used for both arms. Lamivudine will be used with all children. The second NRTI will be zidovudine unless the participant has a hemoglobin &lt; 8 gm/dL, in which case it will be Abacavir. Stavudine will be used in the event that a participant is unable to take Abacavir for safety or other reasons.</description>
        </group>
        <group group_id="B2">
          <title>NVP or EFV + 2 NRTIs</title>
          <description>NVP or EFV + 2 NRTIs: Group 2
Nevirapine (NVP) or Efavirenz (EFV) + 2 NRTI
NVP will be used for children &lt; 3 years of age and EFV for children ≥3 years of age. The same NRTI choice strategy will be used for both arms. Lamivudine will be used with all children. The second NRTI will be zidovudine unless the participant has a hemoglobin &lt; 8 gm/dL, in which case it will be stavudine.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="84"/>
            <count group_id="B2" value="86"/>
            <count group_id="B3" value="170"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.9" lower_limit="0.7" upper_limit="6.0"/>
                    <measurement group_id="B2" value="3.1" lower_limit="0.5" upper_limit="5.9"/>
                    <measurement group_id="B3" value="3.1" lower_limit="0.5" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous ART to Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No Previous ART</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Previous ART</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>WHO Clinical HIV stage</title>
          <description>clinical staging is based on standard WHO grading scales found is the document: https://www.who.int/hiv/pub/guidelines/clinicalstaging.pdf</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Stage I (Asymptomatic)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage II (mod. unexplained weight loss)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage III (unexplained severe weight loss)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage IV (HIV wasting syndrome)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4 Percentage</title>
          <description>The percentage represents the percentage of white cells that are CD4 cells.</description>
          <units>% of white cells that are CD4 cells</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>No Previous ART</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14" lower_limit="2" upper_limit="44"/>
                    <measurement group_id="B2" value="16" lower_limit="2" upper_limit="43"/>
                    <measurement group_id="B3" value="16" lower_limit="2" upper_limit="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Previous ART</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31" lower_limit="8" upper_limit="51"/>
                    <measurement group_id="B2" value="30" lower_limit="10" upper_limit="45"/>
                    <measurement group_id="B3" value="30" lower_limit="8" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Viral Load</title>
          <description>0 = below the level of detection (&lt;400 copies per microliter).</description>
          <units>log10copies/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>No Previous ART</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.4" lower_limit="0" upper_limit="6.4"/>
                    <measurement group_id="B2" value="5.5" lower_limit="0" upper_limit="6.4"/>
                    <measurement group_id="B3" value="5.5" lower_limit="0" upper_limit="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Previous ART</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA" lower_limit="NA" upper_limit="NA">Below the level of detection (&lt;400 copies per microliter)</measurement>
                    <measurement group_id="B2" value="NA" lower_limit="NA" upper_limit="NA">Below the level of detection (&lt;400 copies per microliter)</measurement>
                    <measurement group_id="B3" value="NA" lower_limit="NA" upper_limit="NA">Below the level of detection (&lt;400 copies per microliter)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin</title>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.4" spread="1.3"/>
                    <measurement group_id="B2" value="10.6" spread="1.5"/>
                    <measurement group_id="B3" value="10.5" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Result of Baseline Blood Smear for Asexual Parasites</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence-density of Malaria Defined as the Number of Incident Episodes of Malaria Per Time at Risk.</title>
        <time_frame>Time from randomization to at least 24 months of follow up or until end of the study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: LPV/r + 2 NRTIs</title>
            <description>Lopinavir/ritonavir (LPV/r) +2 nucleoside reverse transcriptase inhibitor (NRTI)
The same NRTI choice strategy will be used for both arms. Lamivudine will be used with all children. The second NRTI will be zidovudine unless the participant has a hemoglobin &lt; 8 gm/dL, in which case it will be Abacavir. Stavudine will be used in the event that a participant is unable to take Abacavir for safety or other reasons.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Nevirapine (NVP) or Efavirenz (EFV) + 2 NRTIs</title>
            <description>NVP will be used for children &lt; 3 years of age and EFV for children ≥3 years of age. The same NRTI choice strategy will be used for both arms. Lamivudine will be used with all children. The second NRTI will be zidovudine unless the participant has a hemoglobin &lt; 8 gm/dL, in which case it will be stavudine.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence-density of Malaria Defined as the Number of Incident Episodes of Malaria Per Time at Risk.</title>
          <units>Episodes/ Person-Yr at Risk</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32"/>
                    <measurement group_id="O2" value="2.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>We assumed that the incidence of malaria in Group 2 would be 0.70 episodes per person-year and estimated that we would need a sample of 300 participants for the study to have 80% power to show a 35% reduction in the incidence of malaria in Group 1, at a 2-sided significance level of 0.05. We then observed an incidence of malaria in Group 2 that was higher than anticipated (2.19 episodes/person-yr) and revised the sample size to 150 participants, who would be followed for at least 6 months.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>Negative Binomial Regression</method>
            <param_type>Incidence Rate Ratio</param_type>
            <param_value>0.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.36</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
            <estimate_desc>Group 1 represents the numerator for the rate ratio. Group 2 represents the denominator for the rate ratio.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Uncomplicated Malaria Episodes With Accompanying Adverse Events That Occurred in the 28 Days Following Antimalarial Therapy</title>
        <description>The rates of adverse events, defined as severity grade 2 or higher that are possibly, probably or definitely related to study drugs over the course of the 28-day period after antimalarial therapy with artemether-lumefantrine (AL).</description>
        <time_frame>28 days after antimalarial therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LPV/r + 2 NRTIs</title>
            <description>LPV/r + 2 NRTIs: Group 1
Lopinavir/ritonavir (LPV/r) +2 nucleoside reverse transcriptase inhibitor (NRTI)
The same NRTI choice strategy will be used for both arms. Lamivudine will be used with all children. The second NRTI will be zidovudine unless the participant has a hemoglobin &lt; 8 gm/dL, in which case it will be Abacavir. Stavudine will be used in the event that a participant is unable to take Abacavir for safety or other reasons.</description>
          </group>
          <group group_id="O2">
            <title>NVP or EFV + 2 NRTIs</title>
            <description>NVP or EFV + 2 NRTIs: Group 2
Nevirapine (NVP) or Efavirenz (EFV) + 2 NRTI
NVP will be used for children &lt; 3 years of age and EFV for children ≥3 years of age. The same NRTI choice strategy will be used for both arms. Lamivudine will be used with all children. The second NRTI will be zidovudine unless the participant has a hemoglobin &lt; 8 gm/dL, in which case it will be stavudine.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Uncomplicated Malaria Episodes With Accompanying Adverse Events That Occurred in the 28 Days Following Antimalarial Therapy</title>
          <description>The rates of adverse events, defined as severity grade 2 or higher that are possibly, probably or definitely related to study drugs over the course of the 28-day period after antimalarial therapy with artemether-lumefantrine (AL).</description>
          <units>% uncomplicated malaria episodes w/ AEs</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.0"/>
                    <measurement group_id="O2" value="79.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.13</p_value>
            <method>Cox Proportional-Hazards</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence-density of Malaria Defined as the Number of Incident Episodes of Complicated Malaria Per Time at Risk.</title>
        <time_frame>Time from randomization to at least 24 months of follow up or until end of the study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>LPV/r + 2 NRTIs
LPV/r + 2 NRTIs: Group 1
Lopinavir/ritonavir (LPV/r) +2 nucleoside reverse transcriptase inhibitor (NRTI)
The same NRTI choice strategy will be used for both arms. Lamivudine will be used with all children. The second NRTI will be zidovudine unless the participant has a hemoglobin &lt; 8 gm/dL, in which case it will be Abacavir. Stavudine will be used in the event that a participant is unable to take Abacavir for safety or other reasons.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>NVP or EFV + 2 NRTIs
NVP or EFV + 2 NRTIs: Group 2
Nevirapine (NVP) or Efavirenz (EFV) + 2 NRTI
NVP will be used for children &lt; 3 years of age and EFV for children ≥3 years of age. The same NRTI choice strategy will be used for both arms. Lamivudine will be used with all children. The second NRTI will be zidovudine unless the participant has a hemoglobin &lt; 8 gm/dL, in which case it will be stavudine.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence-density of Malaria Defined as the Number of Incident Episodes of Complicated Malaria Per Time at Risk.</title>
          <units>Episodes/ Person-Yr at Risk</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.024"/>
                    <measurement group_id="O2" value="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>We assumed that the incidence of malaria in Group 2 would be 0.70 episodes per person-year and estimated that we would need a sample of 300 participants for the study to have 80% power to show a 35% reduction in the incidence of malaria in Group 1, at a 2-sided significance level of 0.05. We then observed an incidence of malaria in Group 2 that was higher than anticipated (2.19 episodes/person-yr) and revised the sample size to 150 participants, who would be followed for at least 6 months.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.87</p_value>
            <method>Negative Binomial Regression</method>
            <param_type>Incidence Rate Ratio</param_type>
            <param_value>0.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.06</ci_lower_limit>
            <ci_upper_limit>11.16</ci_upper_limit>
            <estimate_desc>Group 1 represents the numerator for the rate ratio. Group 2 represents the denominator for the rate ratio.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimates of the 6-month Risk of a First Episode of Malaria</title>
        <description>To assess the effect of ART independently of potential interactions with antimalarial therapy after treatment for malaria, we compared the two groups with respect to the time to the first episode of malaria. Cumulative risk was estimated using the Kaplan-Meier product-limit formula.</description>
        <time_frame>Enrollment to 6 months follow up</time_frame>
        <population>Among patients who were followed for 6 months, malaria did not develop in 34 patients in the NNRTI group and 44 in the lopinavir–ritonavir group; data on 10 patients in the NNRTI group and 7 in the lopinavir–ritonavir group were censored before the 6-month follow-up assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>LPV/r + 2 NRTIs</title>
            <description>LPV/r + 2 NRTIs: Group 1
Lopinavir/ritonavir (LPV/r) +2 nucleoside reverse transcriptase inhibitor (NRTI)
The same NRTI choice strategy will be used for both arms. Lamivudine will be used with all children. The second NRTI will be zidovudine unless the participant has a hemoglobin &lt; 8 gm/dL, in which case it will be Abacavir. Stavudine will be used in the event that a participant is unable to take Abacavir for safety or other reasons.</description>
          </group>
          <group group_id="O2">
            <title>NVP or EFV + 2 NRTIs</title>
            <description>NVP or EFV + 2 NRTIs: Group 2
Nevirapine (NVP) or Efavirenz (EFV) + 2 NRTI
NVP will be used for children &lt; 3 years of age and EFV for children ≥3 years of age. The same NRTI choice strategy will be used for both arms. Lamivudine will be used with all children. The second NRTI will be zidovudine unless the participant has a hemoglobin &lt; 8 gm/dL, in which case it will be stavudine.</description>
          </group>
        </group_list>
        <measure>
          <title>Estimates of the 6-month Risk of a First Episode of Malaria</title>
          <description>To assess the effect of ART independently of potential interactions with antimalarial therapy after treatment for malaria, we compared the two groups with respect to the time to the first episode of malaria. Cumulative risk was estimated using the Kaplan-Meier product-limit formula.</description>
          <population>Among patients who were followed for 6 months, malaria did not develop in 34 patients in the NNRTI group and 44 in the lopinavir–ritonavir group; data on 10 patients in the NNRTI group and 7 in the lopinavir–ritonavir group were censored before the 6-month follow-up assessment.</population>
          <units>Cumulative Risk Percentage</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.7" lower_limit="30.9" upper_limit="52.2"/>
                    <measurement group_id="O2" value="52.5" lower_limit="42.0" upper_limit="63.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.14</p_value>
            <method>Cox Proportional-Hazards</method>
            <method_desc>Adjustment for repeated measures in the same patient</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
            <estimate_desc>Group 1 represents the numerator for the hazard ratio. Group 2 represents the denominator for the hazard ratio.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>28-day Risk of Recurrent Parasitemia</title>
        <description>To assess the effect of potential interactions between ART and artemether-lumefantrine, the risks of recurrent parasitemia at 28 days were compared between the two groups.</description>
        <time_frame>28 days after antimalarial therapy</time_frame>
        <population>The risk of recurrence was assessed among patients who had had uncomplicated malaria that had been treated with artemether–lumefantrine.</population>
        <group_list>
          <group group_id="O1">
            <title>LPV/r + 2 NRTIs</title>
            <description>LPV/r + 2 NRTIs: Group 1
Lopinavir/ritonavir (LPV/r) +2 nucleoside reverse transcriptase inhibitor (NRTI)
The same NRTI choice strategy will be used for both arms. Lamivudine will be used with all children. The second NRTI will be zidovudine unless the participant has a hemoglobin &lt; 8 gm/dL, in which case it will be Abacavir. Stavudine will be used in the event that a participant is unable to take Abacavir for safety or other reasons.</description>
          </group>
          <group group_id="O2">
            <title>NVP or EFV + 2 NRTIs</title>
            <description>NVP or EFV + 2 NRTIs: Group 2
Nevirapine (NVP) or Efavirenz (EFV) + 2 NRTI
NVP will be used for children &lt; 3 years of age and EFV for children ≥3 years of age. The same NRTI choice strategy will be used for both arms. Lamivudine will be used with all children. The second NRTI will be zidovudine unless the participant has a hemoglobin &lt; 8 gm/dL, in which case it will be stavudine.</description>
          </group>
        </group_list>
        <measure>
          <title>28-day Risk of Recurrent Parasitemia</title>
          <description>To assess the effect of potential interactions between ART and artemether-lumefantrine, the risks of recurrent parasitemia at 28 days were compared between the two groups.</description>
          <population>The risk of recurrence was assessed among patients who had had uncomplicated malaria that had been treated with artemether–lumefantrine.</population>
          <units>Cummulative Risk Percentage</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" lower_limit="8.7" upper_limit="22.2"/>
                    <measurement group_id="O2" value="40.8" lower_limit="33.9" upper_limit="48.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Cox Proportional-Hazards</method>
            <method_desc>Adjustment for repeated measures in same participant.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.14</ci_lower_limit>
            <ci_upper_limit>0.68</ci_upper_limit>
            <estimate_desc>Group 1 represents the numerator for the hazard ratio. Group 2 represents the denominator for the hazard ratio.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>63-day Risk of Recurrent Malaria</title>
        <description>To assess the effect of potential interactions between ART and artemether-lumefantrine, the risks of recurrent malaria at 63 days were compared between the two groups.</description>
        <time_frame>28 days after antimalarial therapy</time_frame>
        <population>The risk of recurrence was assessed among patients who had had uncomplicated malaria that had been treated with artemether–lumefantrine.</population>
        <group_list>
          <group group_id="O1">
            <title>LPV/r + 2 NRTIs</title>
            <description>LPV/r + 2 NRTIs: Group 1
Lopinavir/ritonavir (LPV/r) +2 nucleoside reverse transcriptase inhibitor (NRTI)
The same NRTI choice strategy will be used for both arms. Lamivudine will be used with all children. The second NRTI will be zidovudine unless the participant has a hemoglobin &lt; 8 gm/dL, in which case it will be Abacavir. Stavudine will be used in the event that a participant is unable to take Abacavir for safety or other reasons.</description>
          </group>
          <group group_id="O2">
            <title>NVP or EFV + 2 NRTIs</title>
            <description>NVP or EFV + 2 NRTIs: Group 2
Nevirapine (NVP) or Efavirenz (EFV) + 2 NRTI
NVP will be used for children &lt; 3 years of age and EFV for children ≥3 years of age. The same NRTI choice strategy will be used for both arms. Lamivudine will be used with all children. The second NRTI will be zidovudine unless the participant has a hemoglobin &lt; 8 gm/dL, in which case it will be stavudine.</description>
          </group>
        </group_list>
        <measure>
          <title>63-day Risk of Recurrent Malaria</title>
          <description>To assess the effect of potential interactions between ART and artemether-lumefantrine, the risks of recurrent malaria at 63 days were compared between the two groups.</description>
          <population>The risk of recurrence was assessed among patients who had had uncomplicated malaria that had been treated with artemether–lumefantrine.</population>
          <units>Cumulative Risk Percentage</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.1" lower_limit="20.2" upper_limit="38.3"/>
                    <measurement group_id="O2" value="54.2" lower_limit="46.4" upper_limit="62.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Cox Proportional-Hazards</method>
            <method_desc>Adjustment for repeated measures in the same patient.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.22</ci_lower_limit>
            <ci_upper_limit>0.76</ci_upper_limit>
            <estimate_desc>Group 1 represents the numerator in the hazard ratio. Group 2 represents the denominator in the hazard ratio.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Time from randomization to at least 24 months of follow up or until end of the study</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
          <description>LPV/r + 2 NRTIs
LPV/r + 2 NRTIs: Group 1
Lopinavir/ritonavir (LPV/r) +2 nucleoside reverse transcriptase inhibitor (NRTI)
The same NRTI choice strategy will be used for both arms. Lamivudine will be used with all children. The second NRTI will be zidovudine unless the participant has a hemoglobin &lt; 8 gm/dL, in which case it will be Abacavir. Stavudine will be used in the event that a participant is unable to take Abacavir for safety or other reasons.</description>
        </group>
        <group group_id="E2">
          <title>Group 2</title>
          <description>NVP or EFV + 2 NRTIs
NVP or EFV + 2 NRTIs: Group 2
Nevirapine (NVP) or Efavirenz (EFV) + 2 NRTI
NVP will be used for children &lt; 3 years of age and EFV for children ≥3 years of age. The same NRTI choice strategy will be used for both arms. Lamivudine will be used with all children. The second NRTI will be zidovudine unless the participant has a hemoglobin &lt; 8 gm/dL, in which case it will be stavudine.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Neutropenia/Absolute neutrophil count</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia Platelets, decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Temperature/Fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated ALT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Unintentional weight loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Altered mental status</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Dyspnea/respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Stevens-Johnson Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia Platelets, decreased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>WBC, decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Elevated Temperature</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated ALT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Elevated AST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Severe Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Unintentional weight loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pallor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Rash (non-infectious)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study has limited statistical power for the comparison of uncommon events and limited evaluation of potential cardiotoxic effects, hence future studies of the safety of coadministration of lopinavir–ritonavir and lumefantrine are warranted.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Tamara Clark</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>415-206-8790</phone>
      <email>tamara.clark@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

